NASDAQ$SCYX
Scynexis Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
SCYNEXIS reported financial results for Q1 2022, highlighting BREXAFEMME's commercial progress and ibrexafungerp's clinical advancements.
SCYNEXIS reported Q1 2022 financial results with BREXAFEMME generating $0.7 million in net product revenue. The company's cash balance was $95.2 million as of March 31, 2022, and with a recent public offering, SCYNEXIS expects to fund operations into Q1 2024. Clinical updates included positive results from the FURI and CARES trials and the Phase 3 CANDLE study.
- BREXAFEMME achieved almost 4,000 prescriptions with net revenues of $0.7 million in Q1 2022.
- Commercial insurance plans covered BREXAFEMME for 93 million, or 55% of commercially insured lives as of May 2022.
- SCYNEXIS initiated MARIO, a global Phase 3 study to evaluate ibrexafungerp as an oral step-down treatment for invasive candidiasis (IC).
- Positive results were reported from new interim analyses of the FURI and CARES trials, with 83.2% of combined patients demonstrating a clinical response to oral ibrexafungerp.
Headline financials
Revenue & EPS history
Scynexis · Revenue · Quarterly
$687K
Revenue by segment
Scynexis · $22M total across 2 segments · Q4 2025
- License Agreement Revenue$20.6M+456.8%93.6%
- Product Revenue$1.4M—6.4%
Forward guidance
SCYNEXIS anticipates continued growth and advancement in building a broad antifungal franchise for ibrexafungerp across multiple indications. The company plans to enlarge the prescriber base, expand payer coverage, and grow BREXAFEMME revenues. SCYNEXIS also plans to file a supplemental New Drug Application (sNDA) in recurrent vulvovaginal candidiasis (rVVC) and receive approval for this label expansion by the end of 2022.
Tailwinds
- Expanding payer coverage for BREXAFEMME.
- Growing BREXAFEMME revenues.
- Plan to file a supplemental New Drug Application (sNDA) in recurrent vulvovaginal candidiasis (rVVC).
- Receiving approval for rVVC label expansion by the end of 2022.
- Advancement of IV formulation
Headwinds
- BREXAFEMME may not be accepted by physicians and patients at the rate SCYNEXIS expects.
- Risks inherent in SCYNEXIS' ability to successfully develop and obtain FDA approval for ibrexafungerp for additional indications.
- Unexpected delays may occur in the timing of acceptance by the FDA of an NDA submission.
- SCYNEXIS’ need for additional capital resources.
- SCYNEXIS' reliance on third parties to conduct SCYNEXIS' clinical studies and commercialize its products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
+0.4%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+2.0%
Avg return
30 days after
51%
27 / 53 earnings
Positive
+28.6%
Q1 2025
Best reaction
-38.9%
Q1 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.0% | -19.2% | — | |
| Q4 2025 | +2.9% | +16.1% | +14.6% | |
| Q3 2025 | -5.6% | -4.8% | +4.0% | |
| Q2 2025 | -5.3% | -6.5% | +32.5% | |
| Q1 2025 | +28.6% | +21.9% | -5.3% | |
| Q4 2024 | -1.0% | -5.9% | +1.0% | |
| Q3 2024 | +0.0% | -3.0% | -9.8% | |
| Q2 2024 | -5.4% | -7.0% | -31.7% | |
| Q1 2024 | +1.6% | +10.6% | +20.3% | |
| Q4 2023 | +4.2% | +1.8% | +8.1% | |
| Q3 2023 | +0.3% | -5.0% | -2.1% | |
| Q2 2023 | -8.0% | -1.7% | +13.0% | |
| Q1 2023 | -3.8% | +1.0% | -4.5% | |
| Q4 2022 | +24.8% | +21.1% | +7.1% | |
| Q3 2022 | -14.7% | -12.5% | -5.4% | |
| Q2 2022 | +0.7% | -4.5% | +2.1% | |
| Q1 2022 | +10.7% | +14.4% | +4.3% | |
| Q4 2021 | -14.5% | -17.7% | -45.1% | |
| Q3 2021 | -5.9% | +20.5% | +27.7% | |
| Q2 2021 | -2.2% | -6.2% | -5.8% | |
| Q1 2021 | +11.5% | +21.1% | +5.6% | |
| Q4 2020 | +1.0% | +8.2% | -2.0% | |
| Q3 2020 | +13.3% | +15.4% | +34.0% | |
| Q2 2020 | -2.0% | -2.9% | -28.0% | |
| Q1 2020 | -0.3% | -7.3% | +1.2% | |
| Q4 2019 | -22.7% | -29.7% | +1.0% | |
| Q3 2019 | +3.5% | -1.3% | -34.9% | |
| Q2 2019 | +2.8% | +0.0% | +2.8% | |
| Q1 2019 | -2.6% | -7.8% | -24.0% | |
| Q4 2018 | +19.0% | +37.3% | +45.2% | |
| Q3 2018 | -2.3% | -8.4% | -41.2% | |
| Q2 2018 | -6.1% | -10.1% | -12.2% | |
| Q1 2018 | +8.5% | +7.6% | +52.5% | |
| Q4 2017 | +2.7% | +3.4% | -11.0% | |
| Q3 2017 | -9.3% | -9.3% | +12.9% | |
| Q2 2017 | +1.9% | -2.5% | +35.6% | |
| Q1 2017 | -38.9% | -36.2% | -37.4% | |
| Q4 2016 | +9.0% | +11.9% | -5.2% | |
| Q3 2016 | +4.5% | +18.5% | +14.3% | |
| Q2 2016 | -1.9% | +3.8% | +41.8% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | +6.9% | — | — | |
| Q2 2015 | -3.2% | — | — | |
| Q1 2015 | -4.3% | — | — | |
| Q4 2014 | +5.1% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q3 2014 | -0.8% | — | — | |
| Q2 2014 | +7.7% | — | — | |
| Q2 2013 | +7.7% | — | — | |
| Q1 2014 | +5.7% | — | — | |
| Q1 2013 | +5.7% | — | — | |
| Q4 2013 | +5.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro